Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
July 2022 in “Journal of Investigative Dermatology” February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
April 2023 in “Dermatology practical & conceptual” Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2025 in “Journal of Pharmaceutical Investigation” Low-dose rapamycin microdepots can help regrow hair by activating certain cell processes.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet” 44 citations
,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
3 citations
,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
3 citations
,
April 2017 in “Zahedan Journal of Research in Medical Sciences” Almost all kidney transplant patients had complications from immunosuppressive therapy, with excessive hair growth being the most common.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
2 citations
,
May 2024 in “The Turkish Journal of Gastroenterology” Tacrolimus treatment for autoimmune hepatitis can cause hair loss.
11 citations
,
January 2020 in “Engineered science” February 2026 in “JAAD International”
May 2022 in “Research Square (Research Square)” OBEME effectively enhances wound healing and could be a promising carrier for skin treatments.
July 1995 in “Journal of Dermatological Science” Cyclosporine starts hair growth faster, while minoxidil makes it last longer.
August 2025 in “Journal of the American Academy of Dermatology” 2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.